DKBmed Radio

How will the current research advancements in long-acting ART affect clinicians' ability to provide better care for their patients with HIV? The recent data show that the low uptake and adherence to PrEP may be largely due to the pill burden and potential stigma of daily dosing. How might the newer longer-acting PrEP regimens challenge this reluctance?Post-test for CME credits: https://elit.dkbmed.com/issues/226/test Hosted on Acast. See acast.com/privacy for more information.

In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221) Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218) Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216) Hosted on Acast. See acast.com/privacy for more information.

The primary health concern for all individuals living with HIV should be managing their disease, particularly maintaining adherence to their ART treatment. Yet for many, the more immediate demands of their substance use disorder — whether for stimulants and/or opioids — take precedence and can readily become the central focus of their lives. What signals can help a clinician recognize a substance use disorder? How can they differentiate a clinical SUD from intermittent (even though harmful) substance use? What evidence-based treatments should they consider?Post-test for CME credits: https://elit.dkbmed.com/issues/217/test Hosted on Acast. See acast.com/privacy for more information.

CLAIM CME/CE CREDIT HERE: https://dkbmed.com/programs/209/sections/122/evaluationInfluenza remains a perennial public health threat, and urgent and convenient care providers serve an essential role in treating patients who become infected with the virus. This webinar will help you recognize patients at high risk of severe illness caused by the flu and determine when to use influenza antivirals. Importantly, you will also learn several strategies that can help you avoid inappropriate use of antibiotics. Watch now to enhance your flu season readiness and elevate the care you provide to your patients.Credit available: 1.0 of ANCC, AMA, or AAPA Hosted on Acast. See acast.com/privacy for more information.

Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activity? Questions their treating clinicians may not be able to answer with the most current research.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/215/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/214) Hosted on Acast. See acast.com/privacy for more information.

People living with HIV who've had criminal legal involvement face significant challenges that complicate their ability to remain in the HIV care continuum. Many, while incarcerated, have stopped treatment, and once back in the community have been reluctant to resume ART. Why? What are the key drivers behind their disengagement from care? What can clinicians do to encourage these patients to return to treatment? What strategies have been tried, and what's been shown to work? What does the evidence say?Post-test for CME credits: https://elit.dkbmed.com/issues/213/test Hosted on Acast. See acast.com/privacy for more information.

In this issue: Fatigue. It's one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient's life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/211/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/210) Hosted on Acast. See acast.com/privacy for more information.

In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/209/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/208) Hosted on Acast. See acast.com/privacy for more information.

Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.Post-test for CME credits: https://elit.dkbmed.com/issues/206/test Hosted on Acast. See acast.com/privacy for more information.

Current ART regimens can successfully manage HIV infection in nearly all PLWH. But what happens when a patient with HIV is coinfected with a dangerous pathogen ART alone cannot handle? Two of the most common are hepatitis B and latent tuberculosis infection.Post-test for CME credits: https://elit.dkbmed.com/issues/203/test Hosted on Acast. See acast.com/privacy for more information.

Pregnancy and menopause — for many women, these are two of the most significant healthcare events in their lives. For WLWH (women living with HIV) and their healthcare providers, managing these life-changing periods is often complicated by many questions.Post-test for CME credits: https://elit.dkbmed.com/issues/201 Hosted on Acast. See acast.com/privacy for more information.

Mild asthma. For patients showing wheezing and shortness of breath on moderate exertion, it's one of the most common diagnoses, even when breath sounds are clear and pulmonary function testing is normal. What makes mild asthma “mild”? The key guidelines base the stage of a patient's asthma on how difficult it is to treat. Does that mean the frequency of symptom occurrence? How often a rescue inhaler needs to be used? The frequency and severity of pulmonary exacerbations? How should mild asthma be treated? What are the risks and benefits of short-acting beta agonists versus long-acting beta agonists versus inhaled corticosteroids? Which combinations might be appropriate for which patients?Join us in this issue of ePulmonology Review, as Dr. Fawzy from the Johns Hopkins University School of Medicine's Division of Pulmonary and Critical Care discusses these and other issues important to providing the best care for patients with mild asthma.Post test for CME/CE credit: https://elit.dkbmed.com/issues/197/test Hosted on Acast. See acast.com/privacy for more information.

Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?Post test for CME/CE credit: https://elit.dkbmed.com/issues/195/test Hosted on Acast. See acast.com/privacy for more information.

In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon two front-line clinicians in the fight to end the HIV epidemic in the U.S. — Nicky Mehtani, MD, from UCSF Medical Center in San Francisco, and Vanessa Loukas, NP, from Boston University's Chobanian & Avedisian School of Medicine —to share their clinical approaches.Post test for CME/CE credit: https://elit.dkbmed.com/issues/191/test Hosted on Acast. See acast.com/privacy for more information.

Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum? Hosted on Acast. See acast.com/privacy for more information.

Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum? Hosted on Acast. See acast.com/privacy for more information.

A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.Post test for CME/CE credit: https://elit.dkbmed.com/issues/183/testCompanion newsletter: https://elit.dkbmed.com/issues/182 Hosted on Acast. See acast.com/privacy for more information.

NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate with outcomes of importance in MS? And most important, how can these new biomarkers help clinicians care for their patients with MS now? Join us, as guest author Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego, addresses some of these questions in this issue of eMultipleSclerosis Review.Post test for CME/CE credit: https://elit.dkbmed.com/issues/181/testCompanion newsletter: https://elit.dkbmed.com/issues/180 Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

What's the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic's Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services?These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International Health at the University of Virginia, discusses in this issue of eHIV Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Too many individuals with MS are not receiving access to the most effective care. Why? What's behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

How burdensome is spasticity for patients with MS? What's the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies? These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hepatitis B. It may not be curable yet, but as our knowledge continues to grow, so does our ability to benefit our patients today as we prepare them for tomorrow. That's the focus of this Special HBV Edition of eViralHepatitis Review.The first part of this program presented an evidence-based expert commentary by eViralHepatitis Review Program Director Dr. Mark Sulkowski — Professor of Medicine at Johns Hopkins and Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. This second part is an interview providing more in-depth discussions between Dr. Sulkowski and three of medicine's top CHB experts. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

In her Expert Commentary, Dr. Melanie Ward from West Virginia University's Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Dr. Paul Auwaerter discusses XBB and XBB.1.5 subvariants and the respiratory virus season. Topics: *Why XBB and XBB.1.5 subvariants are more transmissible than other subvariants, but less virulent *Effect of Paxlovid on hospitalization and mortality *Summary of the flu and RSV season *Deciding when to treat a COVID-19 patient Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/1-26-23-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Paul G. Auwaerter, MD, MBA, FIDSA, Clinical Director, Division of Infectious Diseases, Sherrilyn and Ken Fisher Professor of Medicine, Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine Hosted on Acast. See acast.com/privacy for more information.

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices? These are some of the questions advanced practice nurse Dallas Ducar, CEO of Transhealth, discusses in this issue of eHIV Review. Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That's the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.  The first part of this program presented an evidence-based Expert Commentary on the current status of weight gain, obesity, and nutrition among people with CF by guest author Katie McDonald, PhD, MS, RDN, CSP, a clinical dietitian at Primary Children's Medical Center in Salt Lake City. The second part is a podcast interview, providing further in-depth discussions between Katie McDonald and three top CF nutrition experts.  Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient's ART history. How will new and in-development agents affect the equation?Which drug combinations are right? Where does the balance between side effects and adherence lie?These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent's University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorbidities be identified? Join us as we discuss these and other issues with Dr. Todd Brown, Professor of Medicine and Epidemiology at Johns Hopkins University, in this eHIV Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Where's the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. Take our post-test to claim CME credits.To read a companion newsletter click here. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 testing. Topics: *Why are we seeing prolonged antigen positive test results? *Do we know when someone is infectious? For how long? *Speculating on the cause of Paxlovid rebound Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/7-28-22-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine Michael Mina, MD, PhD, Chief Science Officer, eMed, Epidemiologist, Immunologist and Physician See acast.com/privacy for privacy and opt-out information.

Dr. Paul Auwaerter interviews Dr. Michael Mina about COVID-19 immunity. Topics: *Is COVID-19 here to stay? *Immunity evasiveness of Omicron BA.4 and BA.5 *Expectations for the fall and winter 2022 *Thoughts on upcoming booster reformulation *Should you get a booster now or wait? Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/7-28-22-episode/eval Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty Presenting faculty: Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine Michael Mina, MD, PhD, Chief Science Officer, eMed, Epidemiologist, Immunologist and Physician See acast.com/privacy for privacy and opt-out information.

Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient's condition does not meet the accepted MS diagnostic criteria — that need to be investigated? Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University's Hotel Dieu de France Hospital in Beirut, Lebanon, and the Cleveland Clinic's Mellen Center for Multiple Sclerosis, explains strategies to reduce misdiagnosis of MS. Take our post-test to claim CME credits.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn't? What does the evidence say? Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleSclerosis Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, as we discuss these questions in this eHIV Review podcast.Take our post-test to claim CME credits.To read a companion newsletter click here. See acast.com/privacy for privacy and opt-out information.

What was it like for a frontline critical care pulmonologist at the very beginning of the COVID-19 epidemic? On the frontlines as the epidemic became pandemic? What's it like today, with new variants and new in-patient and out-patient treatments? What are the key differences between then and now, what have we learned, and how can we be better prepared for next time? Join us for this ePulmonology Review Special Edition podcast, as Dr. Brian Garibaldi from the Johns Hopkins' Division of Pulmonary and Critical Care Medicine takes us through his experiences battling COVID 19: Then and Now. Take our post-test to claim CME credits. See acast.com/privacy for privacy and opt-out information.

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care? Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explains how these questions can affect clinical care. Take our post-test to claim CME credits.Read this podcast's companion newsletter here. See acast.com/privacy for privacy and opt-out information.